Search - tctmd.com

Displaying 41 - 60 of 148

Sort: Relevancy | Date

Presentation TCT 2023

TCT 412: Geometric Predictors of Stroke After Transcatheter Aortic Valve Replacement

Presenter: Brennan Vogl

October 25, 2023

Presentation TCT 2023

TCT 181: Bovine Arch is Associated with Higher Incidence of Stroke after TAVR

Presenter: Gerardo V. Lo Russo

October 25, 2023

Presentation TCT 2023

TCT 94: ProtEmbo: A Potential Shield Against Stroke and Cerebral Lesions in TAVR; Illustrated Using DW-MRI to Assess Device Efficacy

Presenter: Tobias Schmidt

October 25, 2023

Presentation TVT 2023

Safety and Efficacy of Cerebral Embolic Protection Systems in Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis

Presenter: Mazhed Kheyrbek

June 10, 2023

Presentation TVT 2023

Lessons Learned from the PROTECTED TAVR Trial: Mapping the Future of Cerebral Embolic Protection

Presenter: Samir Kapadia

June 08, 2023

Presentation TVT 2023

The Stroke Issue and When to Consider Cerebral Embolic Protection Devices (CEPD)

Presenter: Tamim Nazif

June 07, 2023

Presentation TCT 2022

TCT 333: Effect of stroke on readmissions and cardiovascularoutcomes in patients with Mitraclip.

Presenter: Nirav Patel

September 19, 2022

Presentation TCT 2022

TCT 332: Clinical outcome of transcatheter aortic valve replacement with TriGUARD 3™ cerebral embolic protection device

Presenter: Sayonara Daal

September 19, 2022

Presentation TCT 2022

TCT 331: Predictors of Valvular and Perivalvular Thrombosis and Relations of Neurological Outcomes after TAVR: ADAPT-TAVR Substudy

Presenter: Yeonwoo Choi

September 19, 2022

Presentation TCT 2022

TCT 329: Cerebral Embolic Protection Devices For Prevention Of Post-Procedural Ischemic Stroke With Transcatheter Aortic Valve Replacement: A SYSTEMATIC REVIEW AND META-ANALYSIS

Presenter: Tanesh Ayyalu

September 18, 2022

Presentation TCT 2022

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

Presenter: Mijin Kim

September 18, 2022

Presentation TCT 2022

TCT 327: Clinical and Radiographic Measures of Stroke-Related Outcomes with Cerebral Embolic Protection Devices During TAVR: A Meta-analysis.

Presenter: Arpanjeet Kaur

September 18, 2022

Presentation TCT 2022

Regulatory Pathways and Clinical Trials After PROTECTED TAVR

Presenter: Alexandra J. Lansky

September 17, 2022

Presentation TCT 2022

New and Novel CEP Devices: Differentiating Features

Presenter: Giora Weisz

September 17, 2022

Presentation TCT 2022

None Use: The Data Are Unconvincing and the Cost Is Prohibitive

Presenter: David J. Cohen

September 17, 2022

Presentation TCT 2022

Selective Use: Only in Vulnerable Patients

Presenter: John K. Forrest

September 17, 2022

Presentation TCT 2022

Systematic Use: Unravelling the Stroke Story

Presenter: Nicolas M. Van Mieghem

September 17, 2022

Presentation TCT 2022

The British Heart Foundation PROTECT TAVI Trial: The Next Round!

Presenter: Daniel J. Blackman

September 17, 2022

Presentation TCT 2022

Other Registry Findings and PROTECTED TAVR: Concordant or Divergent

Presenter: Raj Makkar

September 17, 2022

Presentation TCT 2022

The Journey of CEP from Clean TAVI to PROTECTED TAVR: Lessons Learned

Presenter: Axel Linke

September 17, 2022

Advertisement

TCT 412: Geometric Predictors of Stroke After Transcatheter Aortic Valve Replacement

TCT 181: Bovine Arch is Associated with Higher Incidence of Stroke after TAVR

TCT 94: ProtEmbo: A Potential Shield Against Stroke and Cerebral Lesions in TAVR; Illustrated Using DW-MRI to Assess Device Efficacy

Safety and Efficacy of Cerebral Embolic Protection Systems in Transcatheter Aortic Valve Replacement: A Systematic Review and Meta-analysis

Lessons Learned from the PROTECTED TAVR Trial: Mapping the Future of Cerebral Embolic Protection

The Stroke Issue and When to Consider Cerebral Embolic Protection Devices (CEPD)

TCT 333: Effect of stroke on readmissions and cardiovascularoutcomes in patients with Mitraclip.

TCT 332: Clinical outcome of transcatheter aortic valve replacement with TriGUARD 3™ cerebral embolic protection device

TCT 331: Predictors of Valvular and Perivalvular Thrombosis and Relations of Neurological Outcomes after TAVR: ADAPT-TAVR Substudy

TCT 329: Cerebral Embolic Protection Devices For Prevention Of Post-Procedural Ischemic Stroke With Transcatheter Aortic Valve Replacement: A SYSTEMATIC REVIEW AND META-ANALYSIS

TCT 328: Low-dose or Standard-dose Edoxaban versus Dual Antiplatelet Therapy for Leaflet Thrombus and Cerebral Thromboembolism after Transcatheter Aortic Valve Replacement (TAVR): Subgroup Analysis of the Randomized ADAPT-TAVR Trial

TCT 327: Clinical and Radiographic Measures of Stroke-Related Outcomes with Cerebral Embolic Protection Devices During TAVR: A Meta-analysis.

Regulatory Pathways and Clinical Trials After PROTECTED TAVR

New and Novel CEP Devices: Differentiating Features

None Use: The Data Are Unconvincing and the Cost Is Prohibitive

Selective Use: Only in Vulnerable Patients

Systematic Use: Unravelling the Stroke Story

The British Heart Foundation PROTECT TAVI Trial: The Next Round!

Other Registry Findings and PROTECTED TAVR: Concordant or Divergent

The Journey of CEP from Clean TAVI to PROTECTED TAVR: Lessons Learned

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content